BLA Submission Requirements: Complete Checklist and Filing Guide
A Biologics License Application (BLA) submission requires a complete eCTD package including Form FDA 356h, Module 1 administrative documents, Module 2 summaries (Quality Overall Summary, nonclinical and clinical overviews), Module 3 CMC data (drug substance, drug product, reference standards, lot release), Module 4 nonclinical reports, and Module 5 clinical study reports. BLAs are filed under 21 CFR 601 and submitted electronically through FDA's Electronic Submissions Gateway (ESG). CBER conducts a 60-day filing review, and refuse-to-file (RTF) decisions are issued when submissions are substantially incomplete.
Key Takeaways
Key Takeaways
- BLAs are filed under 21 CFR 601 and Section 351(a) of the PHS Act, requiring demonstration of safety, purity, and potency
- CMC deficiencies account for approximately 40% of BLA refuse-to-file decisions, with incomplete process validation and inadequate potency assays as top causes
- Module 3 for biologics requires comprehensive product characterization including primary/higher-order structure, post-translational modifications, and biological activity
- A pre-BLA meeting (Type B) 6-12 months before submission is strongly recommended to confirm eCTD structure and CMC expectations with CBER
- The PDUFA VII BLA application fee for FY 2026 exceeds $4 million; first-time small business applicants may qualify for a waiver
- BLA submission requirements are defined by 21 CFR Part 601 and further specified in FDA guidance documents, ICH M4 (eCTD organization), and CBER-specific recommendations. A BLA demonstrates that a biological product is safe, pure, and potent (21 CFR 600.3) and that the manufacturing facility meets current good manufacturing practice (cGMP) standards under 21 CFR Parts 210, 211, and 600-680.
- Filing a BLA represents the culmination of years of product development. A refuse-to-file (RTF) decision wastes months and forces resubmission. Understanding common BLA rejection reasons is essential for preventing these delays. This guide provides a complete checklist of what CBER expects in each eCTD module, with specific attention to the BLA-specific elements that differentiate it from an NDA.
- In this guide, you will learn:
- Complete Module 1 requirements including Form 356h and BLA-specific administrative documents
- Module 2 summary expectations for biologics
- Module 3 CMC requirements for product characterization, manufacturing, and lot release
- Module 4 and 5 content expectations
- Common refuse-to-file causes and how to prevent them
- Pre-BLA meeting strategy and submission logistics
- ---
BLA Filing Requirements: Regulatory Framework Under 21 CFR 601
A Biologics License Application (BLA) is the regulatory submission filed under Section 351(a) of the Public Health Service Act (42 U.S.C. 262) requesting FDA approval to introduce, or deliver for introduction, a biological product into interstate commerce. The BLA must contain sufficient data to demonstrate safety, purity, and potency of the product, and adequacy of the manufacturing process and facilities.
Legal and Regulatory Basis
| Authority | Citation | Requirement |
|---|---|---|
| PHS Act Section 351(a) | 42 U.S.C. 262(a) | Biological product license requirement |
| BLA regulations | 21 CFR 601.2 | Content and format of BLA |
| Biologics standards | 21 CFR Parts 600-680 | Product standards (potency, purity, safety) |
| cGMP for biologics | 21 CFR 210, 211, 600-680 | Manufacturing requirements |
| Electronic submission | 21 CFR 601.2(a) | eCTD format, ESG submission |
| User fees | PDUFA VII (2022-2027) | Application fee required |
| Environmental assessment | 21 CFR Part 25 | EA or categorical exclusion claim |
BLA vs NDA: Key Differences in Requirements
| Requirement | BLA (Biologics) | NDA (Drugs) |
|---|---|---|
| Governing statute | PHS Act Section 351 | FD&C Act Section 505 |
| Governing regulation | 21 CFR 601 | 21 CFR 314 |
| Application form | Form FDA 356h | Form FDA 356h (same form) |
| Review center | CBER or CDER (product-dependent) | CDER |
| Safety/Efficacy standard | Safe, pure, and potent | Safe and effective |
| Manufacturing | Establishment license included in BLA | Establishment registration separate |
| Lot release | May require CBER lot release testing (21 CFR 610.2) | Not applicable |
| Reference standards | CBER reference standards may be required | USP reference standards |
Under the current CBER/CDER Intercenter Agreement, CBER reviews BLAs for vaccines, blood products, allergenic products, cell therapies, and gene therapies. CDER reviews BLAs for most therapeutic proteins including monoclonal antibodies, cytokines, growth factors, enzymes, and immunomodulators. CDER also retains review authority for insulin and human growth hormone, which transitioned from NDA to BLA status in March 2020 under BPCIA.
BLA Checklist: Module 1 Administrative Documents
Module 1 of the eCTD for a BLA contains administrative and prescribing information specific to the US region.
Module 1 Complete Checklist
| Section | Document | Required? | Notes |
|---|---|---|---|
| 1.1 | Cover letter | Yes | Signed by authorized representative |
| 1.2 | Form FDA 356h | Yes | Application form for BLA |
| 1.3.1 | Patent information (Form FDA 3542a) | Yes | Orange Book listing for biologics |
| 1.3.2 | Patent certification (Form FDA 3542) | If applicable | For 351(k) biosimilar BLAs |
| 1.3.3 | Exclusivity claim | If applicable | Orphan, pediatric, BPCIA exclusivity |
| 1.3.4 | Pediatric study plans | Yes | Under PREA (21 CFR 314.55) unless waiver granted |
| 1.3.5 | PDUFA user fee cover sheet (Form FDA 3397) | Yes | Payment confirmation |
| 1.4 | Field copy certification | Yes | Certify manufacturing site inspection readiness |
| 1.5.1 | Labeling - prescribing information (PI) | Yes | Structured Product Labeling (SPL) format |
| 1.5.2 | Labeling - patient labeling | If applicable | Medication Guide or PPI if required |
| 1.5.3 | Labeling - container/carton labels | Yes | All proposed commercial labels |
| 1.6 | Environmental assessment or categorical exclusion | Yes | Under 21 CFR Part 25 |
| 1.7 | REMS | If applicable | Risk Evaluation and Mitigation Strategy |
| 1.12 | Pre-submission correspondence | Recommended | Pre-BLA meeting minutes, FDA feedback letters |
| 1.14 | Debarment certification | Yes | Under 21 U.S.C. 335a |
| 1.15 | Financial disclosure | Yes | For clinical investigators (21 CFR Part 54) |
Form FDA 356h: BLA-Specific Fields
Form 356h is the unified application form for NDAs and BLAs. For BLAs, the following sections require particular attention:
| Field | BLA-Specific Content |
|---|---|
| Item 3: Application Type | Check "BLA" (351(a) or 351(k)) |
| Item 4: Applicant Information | Legal entity holding the biologics license |
| Item 5: Product Information | Proper name, proprietary name, dosage form, route |
| Item 7: Proposed Indication | Exact proposed indication statement |
| Item 8: Manufacturing Sites | All sites involved in manufacture, testing, packaging, labeling |
| Item 9: Cross-References | IND number, DMFs, reference product BLA (for 351(k)) |
| Item 11: Certifications | Clinical data integrity, debarment, financial disclosure |
CBER issues refuse-to-file (RTF) decisions for missing or incomplete Form 356h information. Before submission, verify that every manufacturing site is listed on Form 356h with the correct FEI number, that the proposed indication matches the clinical data, and that all required certifications are signed. A missing manufacturing site on 356h is a common RTF trigger.
Biologics License Application Checklist: Module 2 Summaries
Module 2 provides summaries and overviews that allow reviewers to understand the complete application without reading every Module 3-5 report in detail.
Module 2 Structure for BLA
| Section | Content | BLA-Specific Emphasis |
|---|---|---|
| 2.2 | Introduction | Product description, mechanism of action, therapeutic context |
| 2.3 | Quality Overall Summary (QOS) | Drug substance, drug product, reference standards, manufacturing process |
| 2.4 | Nonclinical Overview | Pharmacology, toxicology, integrated assessment |
| 2.5 | Clinical Overview | Efficacy and safety evidence, benefit-risk assessment |
| 2.6 | Nonclinical Written and Tabulated Summaries | Individual study summaries per ICH M4S |
| 2.7 | Clinical Summary | Clinical pharmacology, efficacy, safety summaries per ICH M4E |
Quality Overall Summary (2.3): Critical Elements for Biologics
The QOS for a biologic product must address:
| QOS Element | Required Content |
|---|---|
| Drug substance | Description, manufacturing process, characterization, specification, reference standards, container closure, stability |
| Drug product | Description, formulation, manufacturing process, excipient control, specification, reference standards, container closure, stability |
| Facilities and equipment | All manufacturing sites, equipment qualification, environmental controls |
| Adventitious agent safety | Risk assessment, clearance studies, testing strategy |
| Regional information | Any US-specific manufacturing or testing information |
| Comparability | Summary of all manufacturing changes and comparability assessments during development |
The QOS should be a self-contained document that allows a quality reviewer to understand the entire CMC package. CBER reviewers frequently use the QOS as the primary review document and refer to Module 3 for supporting detail. A well-written QOS that anticipates reviewer questions (e.g., justification for specification limits, explanation of atypical results) significantly reduces information requests during review.
Module 3 CMC: Product Characterization and Manufacturing
Module 3 is typically the largest and most complex module in a BLA. For biologics, the CMC requirements under 21 CFR 601.2 and ICH M4Q go beyond what is required for small molecule NDAs.
Module 3 Structure for Biologics
| Section | Content | Key Requirements |
|---|---|---|
| 3.2.S.1 | General Information | Nomenclature, structure (primary, higher-order), mechanism of action |
| 3.2.S.2 | Manufacture | Manufacturing process, process controls, process validation |
| 3.2.S.3 | Characterization | Elucidation of structure, physicochemical properties, biological activity |
| 3.2.S.4 | Control of Drug Substance | Specification, analytical procedures, validation, batch analysis |
| 3.2.S.5 | Reference Standards | Establishment, qualification, traceability to CBER/WHO reference |
| 3.2.S.6 | Container Closure System | Materials, specifications, compatibility |
| 3.2.S.7 | Stability | Long-term, accelerated, stress studies per ICH Q5C |
Product Characterization Requirements (3.2.S.3)
For biological products, characterization must be comprehensive because the manufacturing process defines the product.
| Characterization Category | Analyses Required | Regulatory Basis |
|---|---|---|
| Primary structure | Amino acid sequence, peptide mapping, N/C-terminal analysis, disulfide bonds | ICH Q6B |
| Higher-order structure | Circular dichroism, FTIR, X-ray crystallography (if available) | ICH Q6B |
| Post-translational modifications | Glycosylation (glycan mapping, sialylation), deamidation, oxidation, glycation | ICH Q6B |
| Size variants | SEC-HPLC, AUC, DLS (aggregates); CE-SDS, SDS-PAGE (fragments) | ICH Q6B |
| Charge variants | IEF, cIEF, ion exchange chromatography | ICH Q6B |
| Biological activity | Potency assay (cell-based, binding, enzymatic) | 21 CFR 610.10 |
| Impurity profiles | Process-related (HCP, DNA, protein A); product-related (aggregates, fragments, charge variants) | ICH Q6B |
| Adventitious agents | Sterility, mycoplasma, viral safety evaluation | 21 CFR 610.12, ICH Q5A |
Lot Release Testing Requirements
Under 21 CFR 610.2, CBER may require lot release testing for certain biological products. This means each manufactured lot must be tested and released by CBER before commercial distribution.
| Requirement | Details |
|---|---|
| Products subject to lot release | Vaccines, blood products, allergenic products, some cell therapies |
| Exempt products | Most therapeutic proteins (monoclonal antibodies, cytokines) |
| Submission | Samples and protocols submitted to CBER Division of Product Quality |
| Timeline | CBER targets release within 14 business days |
| Testing performed | Potency, purity, identity, safety tests as defined in 21 CFR 610 |
For products not subject to routine lot release, the manufacturer must still perform all release testing and maintain records per cGMP.
Reference Standards for Biologics (3.2.S.5)
| Standard Type | Purpose | Requirements |
|---|---|---|
| Primary reference standard | Calibration of working standards and qualification of batches | Fully characterized with complete data package; manufactured representative of commercial process |
| Working reference standard | Day-to-day use in release and stability testing | Calibrated against primary reference standard |
| CBER reference standard | Independent reference for potency assignment (if available) | Obtained from CBER, used per CBER protocols |
| WHO International Standards | Global harmonization of potency units | Used to calibrate in-house standards (if applicable) |
FDA's analysis of BLA refuse-to-file decisions shows that CMC deficiencies are the leading cause of RTF actions for biologics, accounting for approximately 40% of RTF decisions. Common Module 3 deficiencies include incomplete process validation, inadequate comparability data for manufacturing changes, and insufficient potency assay qualification.
Module 4 and Module 5: Nonclinical and Clinical Data
Module 4: Nonclinical Study Reports
| Section | Content | BLA-Specific Notes |
|---|---|---|
| 4.2.1 | Pharmacology studies | Primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology |
| 4.2.2 | Pharmacokinetics | ADME studies, immunogenicity impact on PK |
| 4.2.3 | Toxicology | Repeat-dose toxicity, reproductive toxicology, genotoxicity (usually not applicable for biologics per ICH S6(R1)) |
| 4.3 | Literature references | Published nonclinical data supporting the application |
Biologics-specific nonclinical considerations:
- Genotoxicity studies are generally not required for biotechnology-derived products (ICH S6(R1))
- Carcinogenicity studies are generally not required unless there is cause for concern (ICH S6(R1))
- Reproductive toxicology should use relevant species where the product is pharmacologically active
- Tissue cross-reactivity studies (immunohistochemistry) may be required for monoclonal antibodies
- Anti-drug antibody (ADA) assessment in animals should be included
Module 5: Clinical Study Reports
| Section | Content | Requirements |
|---|---|---|
| 5.2 | Tabular listing of all clinical studies | Every study conducted under the IND |
| 5.3.1 | Biopharmaceutic studies | Bioavailability, comparative PK |
| 5.3.2 | Clinical pharmacology | PK, PD, dose-response, drug interaction studies |
| 5.3.3 | Clinical efficacy reports | Controlled studies supporting the indication |
| 5.3.4 | Clinical safety reports | Integrated safety analysis per ICH E2E |
| 5.3.5 | Literature references | Published clinical data |
| 5.3.6 | Post-marketing reports | Not applicable for original BLA |
Biologics-specific clinical considerations:
- Immunogenicity assessment is critical: incidence, clinical impact, neutralizing antibody analysis
- Clinical studies must address the three-legged stool: efficacy, safety, and immunogenicity
- Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) are expected
- Long-term safety data requirements may exceed what is standard for small molecules
Pre-BLA Meeting: Preparation and Strategy
A pre-BLA meeting (Type B, per FDA Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products, 2017) is strongly recommended.
Pre-BLA Meeting Request
| Element | Requirement |
|---|---|
| Meeting type | Type B (scheduled within 60 days of request) |
| Request submission | To the IND, at least 30 days before desired date |
| Briefing document | Due at least 30 days before meeting |
| Recommended timing | 6-12 months before planned BLA submission |
Pre-BLA Briefing Document Content
| Topic | Questions to Address |
|---|---|
| CMC | Manufacturing process adequacy, comparability approach for changes, specification justification, stability protocol adequacy |
| Nonclinical | Completeness of nonclinical package, any outstanding studies |
| Clinical | Adequacy of efficacy and safety databases, primary endpoint analysis plan, immunogenicity assessment plan |
| Regulatory | Proposed indication wording, REMS need, pediatric requirements, exclusivity claims |
| Labeling | Key labeling elements, warnings/precautions, dosing recommendations |
Use the pre-BLA meeting to confirm the eCTD structure with CBER, clarify any outstanding CMC questions, and align on the clinical data presentation. Bring a proposed Module 2 table of contents and ask CBER to confirm the organization is acceptable. This prevents structural issues that can trigger information requests during review.
Common Refuse-to-File Causes and Prevention
Under 21 CFR 601.2(a), CBER conducts a 60-day filing review to determine if the BLA is sufficiently complete to permit substantive review.
Top RTF Causes for BLAs
| RTF Cause | Frequency | Prevention |
|---|---|---|
| Incomplete CMC data | Most common | Ensure process validation, comparability, and stability data are complete |
| Missing manufacturing site information | Common | List all sites on Form 356h with FEI numbers |
| Inadequate potency assay | Common | Qualify potency assay before BLA; demonstrate specificity, linearity, precision |
| Insufficient clinical data | Moderate | Confirm adequacy at pre-BLA meeting |
| Missing environmental assessment | Occasional | File EA or claim categorical exclusion with supporting justification |
| Labeling deficiencies | Occasional | Submit complete PI, patient labeling, container labels |
| Financial disclosure gaps | Occasional | Collect Form FDA 3454/3455 from all investigators |
Pre-Submission Quality Review Checklist
Before submitting the BLA, verify:
- [ ] All eCTD modules are populated and cross-referenced correctly
- [ ] Form 356h is complete with all manufacturing sites and FEI numbers
- [ ] PDUFA fee has been paid and Form 3397 is included
- [ ] All clinical study reports are finalized (not draft)
- [ ] Potency assay is qualified with complete validation report
- [ ] Process validation report covers at least 3 consecutive commercial-scale lots
- [ ] Stability data supports proposed shelf life claim
- [ ] Reference standard is fully characterized and documented
- [ ] Environmental assessment or categorical exclusion is included
- [ ] Financial disclosure forms are collected for all investigators
- [ ] Debarment certification is signed
- [ ] Labeling is in SPL format with correct PLR formatting
- [ ] Pre-BLA meeting minutes are included in Module 1.12
- [ ] eCTD validation passes FDA's ESG technical validation without errors
BLA Submission Logistics
Electronic Submission Requirements
| Requirement | Specification |
|---|---|
| Format | eCTD (ICH M4 v4.0 or current version accepted by FDA) |
| Submission gateway | FDA Electronic Submissions Gateway (ESG) |
| Validation | Must pass FDA technical validation |
| File formats | PDF (PDF/A preferred), XML backbone, SAS transport files for datasets |
| Size limits | Individual files should not exceed 100 MB |
| Sequence numbering | 0000 for original BLA submission |
PDUFA Fee Schedule (FY 2026)
| Fee Type | Amount (FY 2026) |
|---|---|
| Application fee (with clinical data) | Approximately $4.4M |
| Application fee (without clinical data) | Approximately $2.2M |
| Small business waiver | First human drug application fee waived |
| Establishment fee | Approximately $425K annually |
| Product fee | Approximately $125K annually |
Under PDUFA VII (2022-2027), the BLA application fee for FY 2026 exceeds $4 million. First-time applicants qualifying as small businesses (annual revenue under $50 million) may request a waiver of the application fee. This waiver applies only to the first application; subsequent BLAs require full fee payment.
A BLA is filed under Section 351 of the PHS Act for biological products and requires demonstration of safety, purity, and potency. An NDA is filed under Section 505 of the FD&C Act for drug products and requires demonstration of safety and effectiveness. For a detailed comparison, see our BLA vs NDA guide. The BLA includes the establishment license (manufacturing facility approval) within the application, whereas NDA applicants register establishments separately.
Key Regulatory References
| Reference | Citation |
|---|---|
| PHS Act Section 351 | 42 U.S.C. 262 |
| BLA Regulations | 21 CFR Part 601 |
| Biologics Standards | 21 CFR Parts 600-680 |
| Lot Release | 21 CFR 610.2 |
| Potency | 21 CFR 610.10 |
| Sterility | 21 CFR 610.12 |
| Identity | 21 CFR 610.14 |
| Purity | 21 CFR 610.13 |
| Financial Disclosure | 21 CFR Part 54 |
| Environmental Assessment | 21 CFR Part 25 |
| ICH M4 (eCTD) | Common Technical Document Organization |
| ICH Q6B | Specifications for Biotechnological Products |
| ICH Q5C | Stability of Biotechnological Products |
| ICH S6(R1) | Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals |
| PDUFA VII | Public Law 117-180 (2022) |